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Carotid Artery in Patients with Normal Cholesterol
J.A. Reid,1* C. Wolsley,2 L.L. Lau,1 R.J. Hannon,1 B. Lee,1 I.S. Young3 and C.V. Soong11Regional Vascular and Endovascular Unit, Belfast City Hospital, 2Department of Medical Physics, Royal
Victoria Hospital, and 3Queens University Belfast, Belfast, UKObjective. Carotid intima media thickness (IMT) is a good indicator of the severity of atherosclerotic disease. Statins have
been found to reduce carotid IMT in patients with hypercholesterolaemia. The aim of this study was to investigate if
pravastatin is effective in reducing IMT in normocholesterolaemic patients with carotid artery disease.
Methods. Patients with carotid artery stenosis and normal cholesterol levels who were not on a statin, were recruited.
Patients were randomised to receive pravastatin or placebo daily. Serum concentration of cholesterol and IMT of common
carotid arteries were measured before randomisation and at 3 monthly intervals thereafter, for 9 months. IMT was analysed
to give the mean of a standardised 2 cm of the common carotid artery (CCA). Results are expressed as median (IQR) and
comparison made using the Wilcoxon signed ranks test.
Results. Fifty-four patients were examined. Twenty-eight patients were randomised to active treatment. There was no
difference in demographic details and co-morbid states between the two groups. A significant reduction in cholesterol
concentration was observed from 3 months in patients randomised to the pravastatin group [5.14(4.72–5.88) vs. 4.11(3.44–
5.33), p!0.05], while there was also a significant decrease in combined IMT form 6 months [1.53(1.36–1.87) vs. 1.41
(1.33–1.78), p!0.05].
Conclusions. The results demonstrate that pravastatin reduces intima media thickness of the common carotid artery in
normocholesterolaemic patients with moderate carotid stenosis.Keywords: Intima media thickness; Carotid artery; Normal cholesterol.Introduction
Various non-invasive markers of early arterial wall
alteration are currently available, such as arterial wall
thickening and stiffening, endothelial dysfunction and
coronary artery calcification.1 Intima media thickness
(IMT) of the common carotid artery was rec-
ommended as a useful parameter to assess the
presence of coronary artery disease in a recent
publication of the American Heart Association.2 IMT
is the combined thickness of the arterial intima and
media as measured on B-mode ultrasound. It is a
relatively simple procedure, and represents a safe,
inexpensive, precise and reproducible measure.3
In observational and epidemiological studies, a
relationship has been found between IMTand a number
of cardiovascular risk factors such as male sex, ageing,
obesity,4 hypertension,5,6 hypercholesterolaemia,7,8
diabetes9,10 and cigarette smoking.11,12 Severaling author. J.A. Reid, MRCS, Specialist Registrar,
ery, Royal Victoria Hospital, Grosvenor Rd, Belfast
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primary prevention have tested the predictive value of
IMT with regard to clinical cardiovascular compli-
cations13–18 such as myocardial infarction or stroke.
All these studies are concordant in demonstrating that
increased IMT is a powerful predictor of coronary and
cerebrovascular complications. The quantitative value,
reproducibility and high precision of carotid IMT
measurement means it is more and more frequently
used in therapeutic trials to test the effects of drugs.
Various trials have demonstrated that lipid-low-
ering drugs, statins, can significantly decrease IMT
progression in patients with hypercholesterolaemia.19–23
The aim of this study was to investigate whether
pravastatin decreased IMT in patients with normal
pre-treatment cholesterol concentrations.Methods
This study was approved by the local Research Ethics
Committee.Eur J Vasc Endovasc Surg 30, 464–468 (2005)
doi:10.1016/j.ejvs.2005.05.007, available online at http://www.sciencedirect.com onved.
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All patients with carotid artery disease referred to the
Vascular Surgery Unit of Belfast City Hospital between
August 2001 and February 2003 were considered.
Carotid duplex was carried out by one of two trained
technicians to confirm the severity of stenosis and
random cholesterol was measured. Patients with
carotid artery disease who were not undergoing
surgery and had cholesterol concentration less than
5.5 mmol/l were included. Patients were excluded if
they were already on a cholesterol-lowering drug or
had previous carotid endarterectomy. Written
informed consent was obtained and demographic
details, relevant history, risk factors for vascular
disease, and current medications were recorded.Randomisation
Patients were randomly assigned in blocks of four in a
blinded fashion to receive treatment with either
pravastatin 40 mg daily or placebo. The statin
medication was initiated and maintained at the target
study dose throughout the duration of the study. All
patients who completed the study demonstrated
compliance with the treatment program through
return visits for prescription refills and clinic visits
for laboratory analysis. Compliance was enhanced
through central control of study medication and
prescriptions and mailed reminders for the timing of
study-related procedures.Carotid B-mode ultrasound
An ATL5000 duplex ultrasound scanner with L4-7 MHz
linear array transducer was used to image both sides
of the neck of each subject. One operator, blinded to
patient treatment or randomisation performed all the
scans. The subjects were asked to lie supine on a
couch. The carotid artery bifurcation was located as a
reference point and then a high resolution, high-
density longitudinal B-mode image of the CCA just
before the bifurcation was visualised. This represented
images showing 2 cm lengths of the distal common
carotid artery. In all cases, an attempt was made to
keep the far wall of the artery parallel with the scanner
head so as to enable a high quality, best resolution
image of the intima and media features of the artery
wall. Images were recorded at each visit and for each
side of the neck. These images were transferred in a
digital format to a PC to be stored and analysed off-
line. The transferred images were composed of the rawdata and retained the original spatial resolution. They
also allowed adjustment of brightness and contrast.
The stored images for each subject were analysed at
the end of the study so that each set of images from the
same side of the neck could be compared for the
different visits. Images were rejected if there was
extensive plaque formation throughout the length of
the vessel or if there was poor repeatability.
The ‘HDILab’ research program, with computer
edge tracking software, was used to measure the
intima-medial thickness (IMT). The edge tracking
software was employed over a 10 mm length of the
far wall of the vessel normally extending over the
region from 1 to 2 cm below the bifurcation. If there
were small areas of plaque formation these were
avoided or omitted from the measurement when
possible. The ability of the edge tracking software to
locate the edge of the intima and media was monitored
visually and when necessary was adjusted manually.
The average thickness and standard deviation along
this 10 mm length was recorded for each image
(Fig. 1).
Baseline measurements were recorded for each
subject before treatment/randomisation. Patients
were reviewed at 3-monthly intervals until termin-
ation of the study. At each follow-up visit, IMT was
measured and a blood sample taken to measure
random cholesterol concentration.Statistical analysis
The calculation of sample size was based on the
estimated change in IMT. It was assumed that the rate
of progression of IMT was 0.2 mm/yearG0.12 (esti-
mated on a 3 year follow-up). It was calculated that 80
patients would be required to achieve 90% power with
significance of 5% after a treatment period of 9 months.
Demographic details were analysed using the c2
test. The changes from baseline of combined IMT of
right and left CCAs were analysed using non-
parametric tests. Data are presented as median
(IQR). As multiple comparisons were made, a
Bonferroni correction was applied which altered the
p value at which statistical significance was achieved
to 0.017. All statistical analysis was performed using
SPSS software (version 10, SPSS Inc., Chicago).Results
Fifty-four patients were recruited and twenty-eight
randomised to active treatment. There was no
significant difference between the major demographicEur J Vasc Endovasc Surg Vol 30, 11 2005
Fig. 1. Image showing edge tracking software to identify
lumen: intima and media: adventitia interfaces.
Table 2. Cholesterol (mmol/l) concentration at 3, 6 and 9 months
following randomisation
Baseline 3 Months* 6 Months* 9 Months*
Pravastatin
(nZ28)
5.14
(4.72–5.88)
4.11
(3.44–5.33)
4.21
(3.67–4.85)
4.21
(3.38–5.19)
Placebo
(nZ26)
5.39
(4.72–5.88)
5.03
(4.30–6.04)
5.35
(4.54–5.96)
5.16
(4.67–5.91)
* Significant difference in change from baseline between placebo
and pravastatin groups.
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groups (Table 1). There was no significant difference
between groups in the use of other cardiovascular
medication including beta-blockers, calcium channel
blockers, aspirin and angiotensin converting enzyme
inhibitors either at the beginning or end of the study.Primary and secondary endpoints
Table 2 shows the serological measurements of
cholesterol concentration at various time points for
the two experimental groups. There was no significant
difference at baseline between placebo and pravastatin
groups in total cholesterol concentration [5.39(4.72–
5.88) vs. 5.14(4.77–5.91), pZ0.7] but as expected there
was a significant decrease from baseline measurement
in the pravastatin group compared to placebo at 3, 6,
and 9 months following randomisation.
IMT was analysed as the combined IMT of the right
and left CCAs. There was again no significant
difference at baseline between placebo and pravastatin
groups [1.52(1.28–1.68) vs. 1.53(1.36–1.87), pZ0.5].
There was a reduction in intima thickness in theTable 1. Clinical risk factors for non-surgical patients randomised
to pravastatin or placebo
Risk factor Placebo
(nZ26)
Pravastatin
(nZ28)
p value
Age, mean (SEM),
year
70(1.5) 71(1.3) 0.77
Sex, male:female 24:9 23:8 0.89
Smoking, n(%) 18(55) 17(55) 0.98
IHD, n(%) 6(18) 7(23) 0.90
Diabetes, n(%) 4(12) 5(16) 0.92
Smoking, past or present history of smoking; IHD, ischaemic heart
disease, past history of myocardial infarction or angina requiring
treatment; diabetes, insulin and non-insulin dependent requiring
treatment, including diet controlled.
Eur J Vasc Endovasc Surg Vol 30, 11 2005pravastatin group compared to the placebo group,
which was significant at 3 months (pZ0.016), 6 months
(pZ0.011) and 9 months (pZ0.01) following randomis-
ation (Table 3). No correlation was demonstrated
between the changes in cholesterol concentration and
IMT in the pravastatin groups of patients (rZK0.18).Discussion
Atherosclerosis is a dynamic process characterised by
vessel wall remodelling that develops over decades,
ultimately manifesting as acute cardiovascular events
in many individuals.24 Epidemiologic and interven-
tional studies using cardiovascular clinical endpoints
require long study periods and large populations to
establish the influence of risk factors and effects of
therapeutic interventions in preventing such disease
outcomes. B mode ultrasonographic imaging permits
non-invasive real-time high resolution imaging of
superficial artery walls, thus, allowing visualisation
of the effects of the atherosclerotic process.
Several observational studies have shown that
individuals with cardiovascular disease have greater
IMT values. The latter has been shown to be associated
with increased risk of clinical symptoms.14,17,25 The
effects of statin therapy on atherosclerosis have been
assessed by high-resolution ultrasonographic
measurement of carotid IMT in a number of studies.
However, the lack of a standardised protocol for
measuring IMT change makes inter-study comparison
difficult. In particular, imaging protocols vary with
respect to the carotid artery selected for measurement,
i.e. right or left CCA, the carotid bulb or internal
carotid artery, as well as the specific segment of theTable 3. Combined IMT(mm) at 3, 6 and 9 months following
randomisation
Baseline 3 Months 6 Months* 9 Months*
Pravastatin
(nZ28)
1.53
(1.36–1.87)
1.54
(1.31–1.85)
1.44
(1.33–1.78)
1.37
(1.30–1.68)
Placebo
(nZ26)
1.52
(1.28–1.68)
1.50
(1.31–1.71)
1.54
(1.32–1.75)
1.47
(1.23–1.84)
* Significant difference in change from baseline between placebo
and pravastatin groups.
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image was taken of the carotid bifurcation at baseline
so that this constant point could be used as a reference
and the IMT measured over an identical segment of
the artery at subsequent visits. The IMT was calculated
using a computer program removing any observer
bias. It was felt that this was the most accurate method
of measuring IMT and the results were, therefore,
reliable as shown by the small interscan variability of
less than 5%.
This double-blinded randomised trial demon-
strated regression of IMT within 6 months and marked
cholesterol reduction in normocholesterolaemic
patients with pravastatin 40 mg compared to placebo.
These results corroborate with those in previous
studies, which have found a significant decrease in
IMT in patients on a statin over a relatively short
period of time. In contrast to this study others
investigated the effect of statins in hypercholester-
olaemic patients. The REGRESS study21 showed that
pravastatin had an effect on both the carotid and
femoral artery walls in patients with angiographic
coronary artery disease and total cholesterol levels
ranging from 4 to 8 mmol/l. The results were
presented as a combined IMT of the carotid and
femoral arteries. The ASAP trial26 compared the effects
of simvastatin and atorvastatin in patients with
familial hypercholesterolaemia. This trial combined
common and internal carotid artery thickness as an
outcome measure and found that atorvastatin signifi-
cantly decreased IMT. The ARBITER study27 investi-
gated patients with elevated cholesterol levels but
found that there was enhanced benefit with more
aggressive lipid lowering even below recommended
guidelines. In this study, we investigated patients with
low to normal pre-treatment cholesterol levels and
differed from previous investigations in that the
patient population had carotid artery disease rather
than coronary artery disease with or hypercholester-
olaemia. This limited our measurement of IMT due to
the presence of severe atherosclerotic involvement of
the ICA in the majority of patients.
A reduction in IMT was evident as early as 6 months
after starting treatment. It seems unlikely that plaque
regression can be related to the lipid lowering proper-
ties of pravastatin after such a short period. However,
pravastatin may exert its antiatherogenic role by
directly affecting the rate of lipid deposition in
macrophages in the atherosclerotic plaque,28 as well
as by improving defective endothelium-dependent
vasodilatation29,30 and reducing platelet thrombus
formation in flowing blood.31 This hypothesis is
reinforced by the lack of correlation between the change
in IMT and cholesterol concentration (rZK0.18).One major limitation of this study is the small
sample size due to the untimely publication of the
MRC/BHF Heart Protection Study in 2002.32 This
resulted in many patients with normal cholesterol
levels being prescribed statin by their general prac-
titioner or referring physician before attending the
vascular unit for assessment of their carotid disease.
In conclusion, the effect of pravastatin treatment on
carotid IMT progression is beneficial even in normo-
cholesterolaemic patients. However, the cholesterol-
lowering effect of pravastatin does not entirely explain
the reduction in IMT. Further placebo-controlled
randomised trial in the future will be difficult due to
the recent publication of the Heart Protection Study,
which provides convincing evidence that statins are
beneficial to all patients with risk factors for cardio-
vascular disease regardless of initial cholesterol
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